47,978 Shares in Perrigo Company plc $PRGO Acquired by Wiregrass Investment Management LLC

Wiregrass Investment Management LLC acquired a new position in shares of Perrigo Company plc (NYSE:PRGO) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 47,978 shares of the company’s stock, valued at approximately $515,000.

Several other large investors also recently bought and sold shares of the company. EverSource Wealth Advisors LLC boosted its position in shares of Perrigo by 116.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock worth $26,000 after buying an additional 1,014 shares in the last quarter. Geneos Wealth Management Inc. lifted its holdings in shares of Perrigo by 439.1% in the first quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after purchasing an additional 786 shares in the last quarter. UMB Bank n.a. grew its position in shares of Perrigo by 161.5% in the fourth quarter. UMB Bank n.a. now owns 1,964 shares of the company’s stock valued at $27,000 after purchasing an additional 1,213 shares during the last quarter. Meeder Asset Management Inc. purchased a new stake in Perrigo in the 4th quarter valued at approximately $28,000. Finally, CWM LLC grew its holdings in Perrigo by 230.0% during the 4th quarter. CWM LLC now owns 2,191 shares of the company’s stock valued at $31,000 after buying an additional 1,527 shares during the last quarter. Institutional investors and hedge funds own 95.91% of the company’s stock.

Perrigo Stock Down 1.0%

Shares of NYSE PRGO opened at $10.48 on Wednesday. The firm has a market cap of $1.45 billion, a P/E ratio of -0.80, a price-to-earnings-growth ratio of 1.26 and a beta of 0.51. The company has a debt-to-equity ratio of 1.45, a quick ratio of 1.59 and a current ratio of 2.72. Perrigo Company plc has a 1 year low of $9.23 and a 1 year high of $28.43. The firm’s 50 day moving average price is $10.64 and its 200 day moving average price is $11.86.

Perrigo (NYSE:PRGO) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.04. Perrigo had a positive return on equity of 9.96% and a negative net margin of 43.50%.The company had revenue of $841.80 million during the quarter, compared to the consensus estimate of $1.04 billion. During the same period in the previous year, the firm posted $0.60 EPS. Perrigo’s revenue was down 7.2% on a year-over-year basis. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. As a group, sell-side analysts anticipate that Perrigo Company plc will post 2.11 earnings per share for the current year.

Perrigo Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 16th. Investors of record on Friday, May 29th were given a dividend of $0.29 per share. The ex-dividend date was Friday, May 29th. This represents a $1.16 annualized dividend and a yield of 11.1%. Perrigo’s dividend payout ratio is -8.85%.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Zacks Research raised Perrigo from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Weiss Ratings raised Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 15th. One equities research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $19.33.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.